Nephrotoxicity of conventional chemotherapeutics: part 1—platinum compounds and antimetabolite agents

Anticancer therapies have significantly improved survival rates in patients with cancer; however, despite prophylactic measures, many conventional chemotherapeutic agents cause acute and chronic kidney injury. This review provides a comprehensive analysis of the incidence, characteristics, and management of platinum-based and anti-metabolite chemotherapeutic agent-associated nephrotoxicity based on the existing literature. Understanding the profiles of these onconephrotoxic agents is essential for optimizing anticancer treatment while minimizing kidney complications.